Nykode Therapeutics ASA
XMUN:5VB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nykode Therapeutics ASA
XMUN:5VB
|
NO |
|
K
|
Knight Therapeutics Inc
F:04K
|
CA |
|
S
|
Signify NV
SWB:G14
|
NL |
|
P
|
Pexip Holding ASA
DUS:4W9
|
NO |
|
D
|
DaVita Inc
F:TRL
|
US |
|
Ocado Group PLC
LSE:OCDO
|
UK |
|
M
|
Metso Oyj
OTC:OUKPF
|
FI |
|
T
|
Theralase Technologies Inc
OTC:TLTFF
|
CA |
|
Elementos Ltd
ASX:ELT
|
AU |
|
S
|
Star Paper Mills Ltd
NSE:STARPAPER
|
IN |
Nykode Therapeutics ASA
Nykode Therapeutics is a biotechnology company that develops DNA-based vaccines and immunotherapy candidates for cancer and infectious diseases. Its main work is to design vaccine programs that train the immune system to recognize specific targets, then move those candidates through research and clinical testing. The company is not a drug seller in the usual sense; it is building a pipeline of experimental medicines around its core vaccine technology. The company’s customers are mainly large pharmaceutical partners, research collaborators, and eventually patients if its products win regulatory approval. Today it makes money mostly through collaboration and licensing deals, research funding from partners, and other biotech-style partnership payments tied to its technology and development programs. If its candidates succeed, future revenue would also come from product sales or royalties. What makes Nykode different is that it sits earlier in the drug value chain than a traditional drugmaker. Instead of manufacturing a broad portfolio of approved medicines, it focuses on creating a platform that can be used to build multiple vaccine candidates from the same underlying technology. That gives it a business model centered on scientific development, partnerships, and long timelines to reach the market.
Nykode Therapeutics is a biotechnology company that develops DNA-based vaccines and immunotherapy candidates for cancer and infectious diseases. Its main work is to design vaccine programs that train the immune system to recognize specific targets, then move those candidates through research and clinical testing. The company is not a drug seller in the usual sense; it is building a pipeline of experimental medicines around its core vaccine technology.
The company’s customers are mainly large pharmaceutical partners, research collaborators, and eventually patients if its products win regulatory approval. Today it makes money mostly through collaboration and licensing deals, research funding from partners, and other biotech-style partnership payments tied to its technology and development programs. If its candidates succeed, future revenue would also come from product sales or royalties.
What makes Nykode different is that it sits earlier in the drug value chain than a traditional drugmaker. Instead of manufacturing a broad portfolio of approved medicines, it focuses on creating a platform that can be used to build multiple vaccine candidates from the same underlying technology. That gives it a business model centered on scientific development, partnerships, and long timelines to reach the market.
Cancer vaccines: Management said Moderna and Merck’s positive Phase III data materially validated individualized neoantigen vaccines and, more broadly, cancer vaccines as a treatment class.
VB10.NEO: Nykode highlighted clinical immune responses across more than 10 tumor types, a reported link between immune response and overall survival, and a manufacturing process of less than 6 weeks.
Abili-T: The randomized Phase II trial of abi-suva plus pembrolizumab in first-line HPV16-positive head and neck cancer is enrolling as planned, with interim results still expected in 2027.
Partnerships: Management did not provide details on partner discussions, but said interest in individualized and off-the-shelf cancer vaccines should increase following the Moderna and Merck data.
Cash: Nykode ended the quarter with $44.8 million in cash and expects its runway to extend into 2028, or into 2029 if it wins the pending tax case.
Tax case: The company expects a draft recommendation from the Tax Appeal Board secretariat in August; a positive outcome would support the longer cash runway.
Pipeline: Nykode is advancing its autoimmune tolerance platform toward its first clinical development program and is exploring abi-suva in earlier-stage head and neck cancer.